Genetic Technologies Limited (GENE) Short Interest Update

Genetic Technologies Limited (NASDAQ:GENE) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 693,700 shares, a drop of 31.0% from the February 15th total of 1,005,760 shares. Based on an average daily volume of 213,432 shares, the short-interest ratio is currently 3.3 days.

Shares of Genetic Technologies (NASDAQ:GENE) opened at $1.33 on Wednesday. The stock has a market capitalization of $20.93, a P/E ratio of -3.59 and a beta of 3.29. Genetic Technologies has a 1-year low of $0.70 and a 1-year high of $2.05.

ILLEGAL ACTIVITY WARNING: “Genetic Technologies Limited (GENE) Short Interest Update” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at

Genetic Technologies Company Profile

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with's FREE daily email newsletter.

Leave a Reply